Cerus: This Blood-Safety Underdog Should Be Earning More Respect (NASDAQ:CERS)
· seekingalpha.com
Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding.
The value proposition around Cerus ( CERS ) has begun to shift in a new and exciting direction. For a long time, the market evaluated Cerus on the basis that th...